In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

PneumRx inflates its coffers with $11.9mm Series C round; up to $33mm

Executive Summary

PneumRx Inc. (device to treat emphysema) has raised $11.9mm through its Series C round. Since the company filed its initial Form D, which stated it may bring in another $8.6mm before closing the financing, PneumRx has indicated it has up to $33mm in capital commitments. The oversubscribed round was co-led by Forbion Capital Partners, Endeavour Vision, and a strategic corporate partner. Current backers Adams Street Partners, Telegraph Hill Partners, Alta Partners, Spray Venture Partners, Silicon Valley Bank, and Leader Ventures also participated. PneumRx will use the proceeds to advance European sales of the RePneu lung volume reduction coil and to perform a pivotal US trial to support a PMA application. Concurrent with the financing, representatives from Forbion and Endeavour joined PneumRx’s board.
Deal Industry
  • Biotechnology
  • Medical Devices
    • Biomaterials
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies

Advertisement
UsernamePublicRestriction

Register